New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.

3 September 2020
Updated results published today in the prestigious New England Journal of Medicine herald the long-term effectiveness of a targeted combination drug therapy given after surgery in patients with high risk early melanoma.
The international study reports that in patients with Stage III BRAF-positive melanoma who were treated with adjuvant targeted therapy, there can be a long-lasting benefit from the treatment in preventing the disease from recurring.
In the Phase III trial, known as COMBI-AD, patients were treated with either a combination of a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) or placebo given after surgery. The trial demonstrated early promising results after 12 months of treatment and significantly improved recurrence-free survival.
This latest publication revealed the effects of treatment have continued to be sustained after five years. In patients who received the combination therapy, 52% had no disease recurrence after five years. By comparison, only 36% of those patients on placebo – which was the standard of care at the time - had no disease recurrence during this time.
“Our research has demonstrated that many patients have long-term benefit on adjuvant combination targeted therapy, and it may be curative in most of those patients,” says co-senior author and Co-Medical Director of Melanoma Institute Australia Professor Georgina Long AO.
The study shows that adjvuant targeted therapy for patients with the BRAF mutation prevents recurrence in high-risk stage III melanoma.
“Melanoma Institute Australia is working closely with our international collaborators to take major steps forward in cancer treatment,” says Professor Long. “These results take us even closer to reaching our goal of zero deaths from melanoma this decade.”
Journal publication:
Reinhard Dummer, M.D., Axel Hauschild, M.D.,Mario Santinami, M.D., Victoria Atkinson, M.D., Mario Mandalà, M.D., John M. Kirkwood, M.D., Vanna Chiarion Sileni, M.D., James Larkin, M.D., Ph.D., Marta Nyakas, M.D., Caroline Dutriaux, M.D., Andrew Haydon, M.B., B.S., Ph.D., Caroline Robert, M.D., Ph.D., Laurent Mortier, M.D., Ph.D., Jacob Schachter, .D., Thierry Lesimple, M.D., Ruth Plummer, M.D., Kohinoor Dasgupta, Ph.D., Eduard Gasal, M.D., Monique Tan, M.D., Georgina V. Long, M.B., B.S., Ph.D., and Dirk Schadendorf, M.D.
(2020) Five-Year Relapse-Free Survival With Adjuvant Dabrafenib Plus Trametinib in Stage III BRAF-Mutant Melanoma. NEJM.
Read online here.

Australasian Melanoma Conference AMC2021
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.

Sharing our knowledge of melanoma on the global stage
As leaders in the field of melanoma, clinicians and researchers from MIA will be sharing their knowledge at the virtual 10th World Congress of Melanoma.

Melanoma patients and their families urged to speak up and put national spotlight on melanoma.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.

An inspiring WA Melanoma Community Forum
There was a wonderful feeling of community support amongst the melanoma patients, families and friends at the WA Melanoma Community Form.

Family of 8-year-old with melanoma calls on all Australians to step up to help save lives
The Price family has decided to share their story to inspire Australians to support research into new melanoma treatments.

Rethinking skin surveillance for high-risk melanoma patients
New research has provided evidence in favour of a structured skin surveillance program for high-risk melanoma patients.

Australia's oldest melanoma survivor steps up to save lives on his 105th birthday
Melanoma research saved Bert's life at 101 and now he wants to give back.

Predicting disease spread in thin melanoma
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.

Exploring our own clinical questions through MIA's new trials initiative
MIA has recently established a new division of our Clinical Trials Program which co-ordinates and manages investigator-led multi-centre trials.

Young researchers awarded Fellowships to pursue innovative treatments for melanoma
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.

Young researchers receive boost to develop innovative treatment for melanoma
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.

Launch of Melanoma March 2021
Aussies urged to leave their footprint on melanoma as efforts step up to save lives from the disease.

Olivia Vivian announced as MIA ambassador
Olivia is using her Ninja star power to shine a spotlight on melanoma prevention - in memory of her dad.

Melanoma breakthrough - neoadjuvant treatment saving lives.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.

Melanoma breakthrough - neoadjuvant therapy saving lives.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.

Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.

Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.

A message to all Australians from melanoma patient Stuart Taylor
Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate.

Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.
A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.

It's 'Game On Mole' this summer!
All Australians are urged to join the fight against melanoma this summer.